S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Better Than Oil Stocks (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Better Than Oil Stocks (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Better Than Oil Stocks (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Better Than Oil Stocks (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Better Than Oil Stocks (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Better Than Oil Stocks (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Better Than Oil Stocks (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Better Than Oil Stocks (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

$14.04
+0.14 (+1.01%)
(As of 02/23/2024 08:52 PM ET)
Today's Range
$13.70
$14.15
50-Day Range
$13.18
$17.29
52-Week Range
$11.09
$18.22
Volume
683,600 shs
Average Volume
1.51 million shs
Market Capitalization
$1.65 billion
P/E Ratio
27.00
Dividend Yield
N/A
Price Target
$25.80

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.8% Upside
$25.80 Price Target
Short Interest
Healthy
5.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.67mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.63 M Sold Last Quarter
Proj. Earnings Growth
25.27%
From $1.82 to $2.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.95 out of 5 stars

Medical Sector

16th out of 936 stocks

Pharmaceutical Preparations Industry

7th out of 422 stocks


CPRX stock logo

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock Price History

CPRX Stock News Headlines

Catalyst Pharmaceuticals, Inc. (CPRX)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Biotech And Pharma Diversification Pays Off
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/25/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CPRX
Employees
82
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$25.80
High Stock Price Target
$30.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+83.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
23.20%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.81 per share
Book Value
$2.89 per share

Miscellaneous

Free Float
103,340,000
Market Cap
$1.65 billion
Optionable
Optionable
Beta
0.93

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives















CPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price target for 2024?

3 brokerages have issued twelve-month price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price targets range from $24.00 to $30.00. On average, they expect the company's stock price to reach $25.80 in the next year. This suggests a possible upside of 83.8% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2024?

Catalyst Pharmaceuticals' stock was trading at $16.81 at the beginning of the year. Since then, CPRX shares have decreased by 16.5% and is now trading at $14.04.
View the best growth stocks for 2024 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 4,690,000 shares, a decrease of 21.3% from the January 15th total of 5,960,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is currently 3.3 days. Approximately 5.1% of the company's stock are short sold.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our CPRX earnings forecast
.

How can I listen to Catalyst Pharmaceuticals' earnings call?

Catalyst Pharmaceuticals will be holding an earnings conference call on Thursday, February 29th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, hitting analysts' consensus estimates of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to the consensus estimate of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 19.32% and a net margin of 17.81%. During the same period last year, the firm earned $0.11 EPS.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.06%), Dimensional Fund Advisors LP (2.21%), Boston Partners (1.31%), Northern Trust Corp (1.21%), Opaleye Management Inc. (1.07%) and LSV Asset Management (1.05%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CPRX) was last updated on 2/26/2024 by MarketBeat.com Staff